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LETTER FROM THE EDITOR
Gene Therapy: Fighting against the Next Plateau
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The concept of gene therapy really emerged as a theo-
retical possibility at the end of the sixties. During the eight-
ies, the gene marking protocol conducted by Steve Rosen-
berg pointed out the feasibility to genetically modify cells
prior to reimplantation into a patient without obvious dele-
terious side eﬀects, and opened a twelve-year long period
of gene therapy clinical trials that have shown to be mostly
unsuccessful in terms of therapeutical interest. At the end
of the nineties, the gene therapy got closer to the reality
with the ﬁrst true cures of X-linked immunodeﬁcient pa-
tients by gene transfer but, on the other hand, with the ﬁrst
death of a patient due to the gene transfer procedure. Some
naive ideas of the biological mechanisms underlying the dis-
eases approached, technical diﬃculties that remain to be im-
proved, sometimes a lack of synergy between the various
partners ...several reasons can help us to a posteriori under-
stand this twelve-year plateau. And although some trials—
opened to inclusion for business or strategical reasons—
could have been avoided, ...this period should not surprise
us. But we know now that this time is over. In the success-
ful Alain Fisher’s clinical trial to treat X-linked immunod-
eﬁcient patients, the natural in vivo selection of genetically
manipulated cells overpassed the technical problems such as
the so poorly eﬃcient gene transfer into true hematopoietic
stem cells with murine retroviral vectors or the potential si-
lencing of the expression of the transgene, and showed us
that gene therapy can work, assuming that we synergistically
combine the various partners. Even if the overall design of
the vectors, one of the key problems in this ﬁeld, has not
been strictly modiﬁed, the gene transfer tools are now accu-
rately produced and characterized according to the pathol-
ogy approached. New viruses such as the inﬂuenza virus or
the lentiviruses are being tested in vitro or in animal mod-
els, taking into account that a vector can dramatically fail to
elicitabiologicaleventandthattheuniversalvectordoesnot,
and may never, exist. The relationships between applied re-
search and basic research is getting more constructive. These
twonaturalpartnersarenowrealizingthatthefailureofgene
therapy reﬂects both some intrinsic technical problems re-
lated to gene therapy and diﬃculties for true and applica-
ble concepts to come out from the basic research environ-
ment.Thebiologicalmechanismsinvolvedinapathologyare
notanymoreconsideredasthecombinationofreversiblesin-
gle events, but as a cascade of synergistic phenomenon that
should be carefully reverted to approach a therapeutical ben-
eﬁt considering that in most of the cases the reversion of a
single gene should not be enough to elicit a cure. Lessons
from the nineties will prompt emerging technologies such
as DNA array, genome analysis, proteomics, cellular therapy,
and gene therapy to cross talk. In addition, even if they still
emphasize an expectation beyond the reality, the messages
coming from the Biotech companies involved in this ﬁeld,
the caritative associations, or the news also get closer to the
reality of gene therapy and less participate into the confu-
sion that featured this ﬁeld for the last ten years. Does it
mean that gene therapy is entering a fully constructive pe-
riod? What should we expect in terms of therapeutical ben-
eﬁt for the patients for the next ten years? At least, it seems
that we have now the possibility to set up the adequate tools
to ﬁght against the next plateau.
∗ E-mail: claude.bagnis@efs.sante.fr
Fax: +33 4 91189598; Tel: +33 4 91189500